SUBSCRIBE Blog with us: BLOGbiotech

GEN News Highlights

• Email
• Print
• Share
• More GEN News Highlights

Jun 14 2007, 11:50 AM EST

ProNAi Assigns Polymun as Manufacturer of DNAi-based Cancer Therapeutic

GEN News Highlights

ProNAi Therapeutics signed a supply agreement with Polymun Scientific to manufacture the company's PNT2258 DNAi®-based cancer therapeutic.

Polymun will use its cross-flow injector technology to produce ProNAi's liposome-formulated candidate, which is in the final stages of preclinical toxicology testing. ProNAi reports that it intends to bring PNT2258 to IND submission later this year.

"ProNAi is confident that Polymun's manufacturing processes and technology are state-of-the-art and up to the task of formulating our oncology drug candidate, which features our novel oligo delivery method for the safe and effective administration of nucleic acid-based therapies," states Richard D. Gill, president and CEO of ProNAi.

 

• Email
• Print
• Share
• More GEN News Highlights

Comment on this News:

Name:
Title:
Comment:
	HELP US FIGHT SPAMMING ROBOTS by answering the following simple question. It will verify you as a legitimate user wishing to post a comment. Thank you for your cooperation.

CAREER CENTER

WEBINARS

PODCASTS

MOST POPULAR